公开(公告)号：US20140228370A1

公开(公告)日：2014-08-14

申请号：US14346859

申请日：2012-09-20

申请人： BAYER INTELLECTUAL PROPERTY GMBH

发明人： Knut Eis ,  Florian Puehler ,  Ludwig Zorn ,  Arne Scholz ,  Philip Lienau ,  Mark Jean Gnoth ,  Ulf Bömer ,  Judith Günther

IPC分类号： A61K31/5025 ,  C07D491/048 ,  A61K45/06 ,  C07D487/04

CPC分类号： A61K31/5025 ,  A61K45/06 ,  C07D487/04 ,  C07D491/048

摘要： The present invention relates to substituted imidazopyridazine compounds of general formula (I): in which A, Q, R1, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

摘要翻译： 本发明涉及通式（I）的取代的咪唑并哒嗪化合物：其中A，Q，R 1，R 3，R 4和n如权利要求中所定义，涉及制备所述化合物的方法，可用于制备所述化合物的中间体化合物 涉及包含所述化合物的药物组合物和组合，以及所述化合物用于制备用于治疗或预防疾病，特别是高增殖性和/或血管生成障碍的药物组合物作为唯一试剂或组合的用途 与其他活性成分。

公开(公告)号：US09962389B2

公开(公告)日：2018-05-08

申请号：US15488155

申请日：2017-04-14

申请人： Bayer Intellectual Property GmbH

发明人： Ulrich Lücking ,  Rolf Bohlmann ,  Arne Scholz ,  Gerhard Siemeister ,  Mark Jean Gnoth ,  Ulf Bömer ,  Dirk Kosemund ,  Philip Lienau ,  Gerd Rühter ,  Carsten Schultz-Fademrecht

IPC分类号： C07D251/44 ,  C07D251/42 ,  C07D251/22 ,  C07D251/16 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07C381/10 ,  A61K31/53 ,  A61P35/00 ,  C07D405/04 ,  C07B59/00

CPC分类号： A61K31/53 ,  C07B59/002 ,  C07B2200/05 ,  C07C381/10 ,  C07D251/16 ,  C07D251/22 ,  C07D251/42 ,  C07D251/44 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).

公开(公告)号：US09320737B2

公开(公告)日：2016-04-26

申请号：US14346859

申请日：2012-09-20

申请人： Bayer Intellectual Property GmbH

发明人： Knut Eis ,  Florian Puehler ,  Ludwig Zorn ,  Arne Scholz ,  Philip Lienau ,  Mark Jean Gnoth ,  Ulf Bömer ,  Judith Günther

IPC分类号： C07D487/04 ,  C07D491/04 ,  A61K31/5025 ,  A61P35/00 ,  A61K45/06 ,  C07D491/048

CPC分类号： A61K31/5025 ,  A61K45/06 ,  C07D487/04 ,  C07D491/048

摘要： The present invention relates to substituted imidazopyridazine compounds of general formula (I): in which A, Q, R1, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

摘要翻译： 本发明涉及通式（I）的取代的咪唑并哒嗪化合物：其中A，Q，R 1，R 3，R 4和n如权利要求中所定义，涉及制备所述化合物的方法，可用于制备所述化合物的中间体化合物 涉及包含所述化合物的药物组合物和组合，以及所述化合物用于制备用于治疗或预防疾病，特别是高增殖性和/或血管生成障碍的药物组合物作为唯一试剂或组合使用 与其他活性成分。